Longer-term follow-up of patients with refractory and relapsed diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR) T cell therapy showed sustained responses in about half of the patients, suggesting that CAR-T therapy may be an effective option for this hard-to-treat non-Hodgkin's lymphoma, according to the ZUMA-1* and JULIET** trials presented at ASH 2017.
Combining aspirin with warfarin led to increased bleeding complications in patients with atrial fibrillation (AF) or venous thromboembolic disease (VTE) compared with warfarin alone, resulting in higher rates of major bleeding events and hospital admissions, according to data presented at ASH 2017.
Defibrotide treatment may be beneficial to adult patients with posthematopoietic stem cell transplantation (HSCT) hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), reports a new study presented at the concluded 59th American Society of Haematology Annual Meeting (ASH 2017).
Use of idelalisib plus ofatumumab in the frontline treatment of chronic lymphocytic leukaemia (CLL) is effective, yielding high overall response rate, although this is counterbalanced by significant toxicities, according to efficacy data from a phase II trial.
In the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), patients presenting BCR-ABL1 transcript levels ≤10 percent at 3 months are more likely to achieve major molecular response at 12 months with faster response rate compared with those who have transcript levels >10 percent, according to ≥12 months of follow-up data from the BFORE* trial.
Treatment with defibrotide is safe and effective for patients with veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following either allogeneic or autologous haematopoietic stem cell transplant (HSCT), according to the results of a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, Georgia.
Once-weekly subcutaneous administration of the bispecific humanized monoclonal antibody emicizumab successfully prevented or reduced bleeds with a favourable safety profile in paediatric patients with haemophilia A with inhibitors in the phase III HAVEN-2* trial, confirming the findings of a previous interim analysis.
Platelet count thresholds <20 x 109/L and <10 x 109/L are associated with major increased risk for both any and mucosal bleeding. Furthermore, platelet count, female sex and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) are risk factors for the risk of any bleeding, according to a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia.
In newly diagnosed, transplant-eligible multiple myeloma (MM) patients, induction therapy with cyclophosphamide-bortezomib-dexamethasone (CyBorD) delivers a comparable efficacy to bortezomib-dexamethasone (Vel-Dex), according to a new study presented at the recently concluded 59th American Society of Hematology Annual Meeting (ASH 2017).
A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.
Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.
Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.
At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.
“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.
Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.